

Investor Presentation

May 2023



FORWARD LOOKING STATEMENTS


This presentation has been prepared by Movano Inc. ("we," "us," "our," "Movano" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development efforts and product releases; clinical trial and regulatory initiatives; commercial partner activities; as well as our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



INTRODUCING THE NEXT GENERATION OF WEARABLES


The Evie Ring is the Only Product that Combines Medical-Grade Technology, Health Data, and Insights for Women





OUR SEASONED TEAM HAS DIVERSIFIED EXPERIENCE & VISION TO SUCCEED


.....





WEARABLE MARKET GROWING EXPONENTIALLY







THE EVIE RING FILLS A UNIQUE NEED NOT CURRENTLY ADDRESSED

•••••••

FITNESS & WELLNESS

INCUMBENT PRODUCTS ARE ONE-SIZE-FITS-ALL

- Serve fitness enthusiasts
- Focus on comms, staying connected
- Quantitatively track performance metrics
- Bring awareness to sleep duration and stages
- Goal-setting



WOMEN

NO EXISTING SOLUTION

- Form factor and sizing designed for women
- Personalized insights derived from AI
- Gamify the process of getting healthier
- Menstrual health prioritized for all stages
- Mental health correlated with passivelycollected ring data
- Medical grade technology

ENTERPRISE

NO EXISTING SOLUTION

- Pharma needs a medical-grade device for clinical trials and post-market surveillance
- Medical device companies need patient status for real-time optimization
- Payors need medical-grade Remote Patient Monitoring (RPM)capabilities
- Retailers are looking for health narrative






uniquely positioned to satisfy these market needs



MOVANO HEALTH'S B2B OPPORTUNITY

.....



<u>1. Grandview Research</u>, 2. <u>CDC</u>, 3. <u>NIH</u>, 4. <u>Healthline</u>, 5. <u>American Lung Association</u>, 6. Company analysis



EVIE DELIVERS ON ALL REQUIREMENTS OF A SUCCESSFUL LAUNCH

.....







WOMEN ARE UNDERSERVED BY THE HEALTHCARE SYSTEM

•••••••





While more connected to the healthcare system, most feel dismissed by providers¹



Heart disease is the #1 cause of death for women in the U.S.²




92% of women feel unprepared for menopause³





WOMEN'S BIGGEST ASK: TRUSTED DATA AND INSIGHTS

....



10

WE ASKED 1000 WOMEN TO TELL US ABOUT THEIR PERSONAL HEALTH JOURNEY...

THIS IS WHAT THEY SAID:

Three-quarters are in the wearable/tracking market, with a third currently tracking via a watch or fitness tracker. She is looking for a **trusted resource** to help her find more energy for her day, strength to engage with family and stay on top of daily tasks.

She wants a more **holistic overview** of her health, beyond a moment in time; no compulsive exercise or counting calories.



Women between the ages of 35 and 75 in a series of 20 min interviews




Currently own or looking to purchase a wearable Nationally representative sample who live in the U.S.

Solves a



FDA-CLEARED RING FOR STRATEGIC PARTNERS









MEET EVIE

••••••••








EXPECT TO FILE FOR FDA CLEARANCE ON SpO₂ & HR DATA IN JUNE 2023

••••••••








PRODUCT ENHANCEMENT OPPORTUNITIES

.....







BETA TESTS WITH WORLD-CLASS PARTNERS

....








EVIE POST LAUNCH RESPONSE CONTINUES TO OUTPERFORM EXPECTATIONS

•••••••








WHO ARE OUR DIRECT CONSUMERS?


.....





STRONG LEAD GEN GROWTH WITH MINIMAL INVESTMENT INDICATES HEALTHY CONSUMER DEMAND

••••








Evie digital campaigns have served over 24M impressions since January



GROWTH PHASES OF MOVANO HEALTH



- Brand Ambassador
- Rally Early Adopters
- FDA Clearance


 Consistent Consumer Growth

Lines and Target Consumers



CORPORATE SNAPSHOT (NASDAQ: MOVE)

....



Inc. Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company's common stock having an aggregate offering price of up to \$50M.



NASDAQ: MOVE

+1 (415) 651-3172 6800 Koll Center Pkwy. Pleasanton, CA 94566 www.movanohealth.com www.eviering.com





BLOOD PRESSURE AND GLUCOSE

•••••••



Our patented System-on-a-Chip was built from the ground up

After four years in development, the smallest ever custom RF-enabled IC designed for blood pressure and glucose monitoring is now functional, providing:

Greater accuracy

Flexibility in form factor

Cost-effective solutions

THE POWER OF 4 CHIPS IN 1

Meet Movano Health's custom mmWave integrated sensor

Actual chip size: 4mm x 6.7mm

Movano Health patent summary

US: 21 Issued, 32 Pending

PCT International applications pending: 1

Foreign: 1 Issued (China), 3 pending (1 China/2 Europe)



Our US patents fall into three families:

RF IC Architecture (3) Issued	 Covers RF IC design, including multi-band mixing and conductor loss mitigation that is critical at high frequencies. Key Issued Patents: Systems for multi-band radar-based sensing (US 11,298,037) Methods for multi-band radar-based sensing (US 10,874,314)
RF-Based Health Monitoring (15) Issued (25) Pending	 Covers signal processing techniques for generating high resolution pulse wave signal to determine HR, BP, BG level, techniques for alignment of RF sensor, techniques related to optical/RF sensor fusion. Key Issued Patents: Systems for RF-based health monitoring utilizing amplitude and phase data (US 11,445,929) Systems for RF-based health monitoring generating alignment signals (US 11,206,993) Methods and systems for monitoring BP using stepped frequency radar with spectral agility (US 11,360,188) Systems for health monitoring using radio waves that include collocated RF components (US 11,464,418) Systems for health monitoring using radio waves that include mixing signals at different frequencies (US 11,583,199) Methods for radio wave based health monitoring that utilize data derived from amplitude and/or phase data (US 11,576,586)-
Machine Learning Applications (2) Issued (8) Pending	 Techniques for generating training data and training ML models for health monitoring, and techniques for utilizing ML models for health monitoring, including blood pressure and blood glucose. Key Issued Patents: Methods for training a model for use in RF-based health monitoring (US 11,464,419) Methods for training a model for use in radio waved based blood pressure monitoring (US 11,596,321)